Skip to main
ADCT

ADC Therapeutics (ADCT) Stock Forecast & Price Target

ADC Therapeutics (ADCT) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ADC Therapeutics's stock outlook is supported by the advancement of its discounted cash flow (DCF)-based valuation, which reflects a raised price target due to positive developments in its clinical studies, specifically the potential for label expansion for ZYNLONTA. The company's strategy to secure funding through a $60 million PIPE financing with institutional investors strengthens its financial position, enabling further investment in its promising development pipeline, including multiple ongoing trials. Moreover, the anticipated outcomes from the multicenter study may enhance the product's market presence, particularly in the second-line treatment setting in combination with existing therapies like rituximab.

Bears say

ADC Therapeutics has outlined significant financial challenges, including a recorded net loss of $0.04 per share in 4Q25, which, while narrower than prior estimates, still indicates ongoing financial struggles. The company faces substantial risks related to the approval and market uptake of its lead product, ADCT-402, as well as potential failures within its pipeline, contributing to a negative outlook. Additionally, the risk of medium- to long-term dilution further exacerbates concerns regarding the firm's financial stability and growth prospects.

ADC Therapeutics (ADCT) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ADC Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ADC Therapeutics (ADCT) Forecast

Analysts have given ADC Therapeutics (ADCT) a Strong Buy based on their latest research and market trends.

According to 3 analysts, ADC Therapeutics (ADCT) has a Strong Buy consensus rating as of Apr 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ADC Therapeutics (ADCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.